H
Hopewell Therapeutics
Synthetic Lipid for Gene Therapy and Genome Editing
About Hopewell Therapeutics
Hopewell Therapeutics is a biotechnology firm concentrated on developing the next generation of genomic medicines through its proprietary tissue-targeted Lipid Nanoparticle (ttLNP) technology. The company was established in 2021, building upon a decade of research from Tufts University. It was scientifically founded by Dr. Qiaobing Xu, a Professor of Biomedical Engineering at Tufts University, who now serves as the company's Chief Technology Officer. Dr. Xu's extensive research forms the basis of Hopewell's intellectual property, which is exclusively licensed from the university. The company is led by President and CEO, Dr. Louis Brenner, an experienced biotech industry executive.
The core of Hopewell's business is its ttLNP platform, which is engineered to deliver a variety of genomic cargoes—such as mRNA, siRNA, DNA, and gene-editing tools—directly to specific tissues and cells outside of the liver (extrahepatic targets). This technology aims to overcome the delivery limitations of current LNP systems, potentially offering better targeting, biocompatibility, and sustained effects with repeat dosing. The firm's business model involves a dual approach: developing its own internal pipeline of therapies and forming strategic partnerships with other industry leaders to leverage its delivery platform. This strategy allows Hopewell to explore a wide range of applications for its technology. The company generates revenue through these partnerships and by advancing its own therapeutic products. The company has secured significant seed financing, raising a total of $32.1 million over two rounds, including a $25 million round in May 2023, to fund its operations, research, and development. Key investors include Mass Ave Capital, 5Y Capital, and HIKE Capital.
Hopewell's primary service is providing a sophisticated, non-viral delivery system for complex genomic medicines. This platform is designed to address unmet medical needs across several challenging disease areas. The initial focus of its internal pipeline is on pulmonary diseases, where preclinical studies have shown successful delivery of genetic material to key cell types in the lungs. Beyond lung diseases, the company is actively exploring applications for its ttLNP platform in oncology, infectious diseases, rare genetic disorders, and neurological conditions. Preclinical data presented at scientific conferences has demonstrated the platform's ability to systemically deliver cargoes to specific cellular targets in the lung, spleen, and liver, as well as targeting various immune cells for vaccine development.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Jun 2023 | $25M | $100M | Hike Capital · BOPU · Massachusetts Avenue Capital · WS Investments | ↗ |
| EARLY VC✓Equity / VC | Feb 2022 | $7.1M | $28M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Hopewell Therapeutics is 1.6K monthly website visits, up 175.9% over the last three months. Hopewell Therapeutics's team grew 66.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hopewell Therapeutics in the Woburn ecosystem
The Hopewell Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Hike Capital- BOBOPU
Massachusetts Avenue Capital
WS Investments- IVIMO Ventures
5Y Capital
Other known investors1 additional known investor
University of Alberta
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hopewell Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hopewell Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









